Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Porto – page 26

498 clinical trials in Porto, Portugal across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Porto at a glance
498
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

498 trials in Porto

Open in trial search

Adenocarcinoma gastric

Not recruiting

Study of Zolbetuximab and CAPOX for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Astellas Pharma Global Development Inc.

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

CDKL5 deficiency disorder

Not recruiting

Study on the Effectiveness and Safety of Fenfluramine Hydrochloride for Patients with CDKL5 Deficiency Disorder

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Fenfluramine Hydrochloride
  • Sponsor:Zogenix International Limited

Idiopathic inflammatory myopathy

Not recruiting

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study on the Effects of FDY-5301 for Patients with Anterior ST-Elevation Myocardial Infarction (Heart Attack)

Not recruiting
Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Iodide
  • Sponsor:Faraday Pharmaceuticals Inc.

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Diffuse large B-cell lymphoma

Not recruiting

Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Eosinophilic oesophagitis

Not recruiting

Study on Budesonide Tablets for Treating Eosinophilic Esophagitis in Adults

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Dr. Falk Pharma GmbH

Chronic obstructive pulmonary disease

Not recruiting

Study on Itepekimab for Former Smokers with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Graft versus host disease+1

Not recruiting

Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Itolizumab
  • Sponsor:Equillium Inc.

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Demyelination

Not recruiting

Study on the Effectiveness and Safety of Rozanolixizumab for Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Porto

What the registry says about research in the country

01 Ophthalmology & Rare Diseases

Innovative research focusing on polypoidal choroidal vasculopathy and rare genetic conditions like PMM2-CDG, exploring new treatment approaches to improve patient outcomes.

  • Vision disorders
  • Genetic disorders
  • Treatment efficacy studies
02 Oncology & Hematology

Groundbreaking studies in chronic myelogenous leukemia, multiple myeloma, and advanced malignancies, including research on novel therapies for non-small cell lung cancer.

  • Blood cancers
  • Solid tumors
  • Immunotherapy
03 Dermatology & Immunology

Comprehensive research into conditions like hidradenitis suppurativa, plaque psoriasis, and pyoderma gangrenosum, evaluating new therapeutic approaches.

  • Inflammatory skin conditions
  • Autoimmune disorders
  • Novel biologics
04 Cardiology & Metabolic Disorders

Studies examining hypertrophic cardiomyopathy, familial hypercholesterolemia, and innovative treatments for obesity.

  • Heart conditions
  • Metabolic diseases
  • Weight management
05 Neurology & Genetic Disorders

Investigating treatments for Dravet Syndrome, menstrual migraine, and rare conditions like Niemann-Pick disease.

  • Neurological disorders
  • Rare diseases
  • Pain management
Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.